Vertex gets EC nod for Kalydeco to treat children and adolescents with cystic fibrosis

This article was originally published here

The approval allows Kalydeco to be used for the treatment of children and adolescents with CF aged between six months and older with a weight of at least

The post Vertex gets EC nod for Kalydeco to treat children and adolescents with cystic fibrosis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply